Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more ...
Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Novo Nordisk said on Wednesday it would begin selling ... as it grapples with shifts to the competitive dynamic of the US obesity drug market. The move comes just over a week after rival Eli ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
New York, New York-- (Newsfile Corp. - March 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...
Novo Nordisk announced that the US Food and Drug Administration (FDA) has determined the shortage of Wegovy and Ozempic is resolved. The FDA's assessment confirms the US supply of these ...
However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns (US$800 million) in relation to the drug after adverse clinical trial results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback